Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
1. Median PFS (5.6 months vs 5.6 months) and median OS (21.4 months vs 18.1 months) were similar in both ...
Tag: belzutifan
#VisualAbstract: Belzutifan is more Effective than Everolimus in Treating Advanced Renal-Cell Carcinoma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Belzutifan plus cabozantinib for immunotherapy pre-treated advanced renal cell carcinoma
1.The objective response rate was 30.8% with the majority attributing to partial response. 2. Most common adverse events (grade 3 ...